Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,082 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Immunodeficiency Virus Type 1 (HIV-1) Clear all
Completed Phase 1 Interventional

Effect of Leflunomide on T Cell Proliferation in HIV-Infected Patients

NCT00101374
View directory record Official record
Conditions
HIV Infections
Interventions
Leflunomide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 14, 2026, 4:36 PM EDT
Completed No phase listed Observational

A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection

NCT00001117
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
42
States / cities
Los Angeles, California • Menlo Park, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2008 · Synced Oct 14, 2026, 4:36 PM EDT
Terminated Phase 2Phase 3 Interventional

Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

NCT06613685
View directory record Official record
Conditions
HIV-1-infection
Interventions
lepetegravir, lenacapavir pacfosacil, Bictegravir/emtricitabine/tenofovir alafenamide, lepetegravir/lenacapavir pacfosacil FDC, Placebo to Match BVY, Placebo to Match GS1720/GS-4182 FDC
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Torrance, California • West Hollywood, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 14, 2026, 4:36 PM EDT
Terminated Phase 2 Interventional Results available

A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

NCT04493216
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, ABC/3TC, FTC/TAF, Dolutegravir, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Ft. Pierce, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 14, 2026, 4:36 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs

NCT00004852
View directory record Official record
Conditions
HIV Infections
Interventions
Efavirenz, Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
46
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 4:36 PM EDT
Completed Not applicable Interventional

A Study of Amprenavir in HIV-Infected Patients

NCT00002405
View directory record Official record
Conditions
HIV Infections
Interventions
Amprenavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
4 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)

NCT01928927
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Telmisartan
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 14, 2026, 4:36 PM EDT
Suspended Phase 3 Interventional

A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

NCT00002362
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Efavirenz, Emtricitabine, Stavudine
Drug
Lead sponsor
Triangle Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
10
States / cities
Sacramento, California • San Francisco, California • Fort Lauderdale, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 4:36 PM EDT
Not listed Phase 3 Interventional

Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy

NCT00008554
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Nelfinavir mesylate, Lamivudine, GW433908
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
23
States / cities
Concord, California • Long Beach, California • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 4:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers

NCT00001088
View directory record Official record
Conditions
HIV Infections
Interventions
APL 400-047, Bupivacaine hydrochloride
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2001
U.S. locations
4
States / cities
Birmingham, Alabama • Rochester, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2008 · Synced Oct 14, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission

NCT00099359
View directory record Official record
Conditions
Disease Transmission, Vertical, Vertical Human Immunodeficiency Virus Transmission, HIV Infections
Interventions
Zidovudine, Nevirapine (NVP), Epivir (3TC), Nelfinavir (NFV)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Up to 2 Days
Enrollment
1,735 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
5
States / cities
Long Beach, California • Gainesville, Florida • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Oct 14, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

NCT00089583
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I
Interventions
LEXIVA (GW433908), Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
2 Years to 18 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 14, 2026, 4:36 PM EDT
Completed No phase listed Observational

A Study to Monitor Patients With Primary or Early HIV Infection

NCT00000911
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Oct 14, 2026, 4:36 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Switching From Epzicom to Truvada

NCT00724711
View directory record Official record
Conditions
HIV Infection
Interventions
emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), abacavir (ABC)/lamivudine (3TC)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
73
States / cities
Little Rock, Arkansas • Beverly Hills, California • Fountain Valley, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 14, 2026, 4:36 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance

NCT04648280
View directory record Official record
Conditions
HIV Infections With Multi Drug Resistant Virus
Interventions
Fostemsavir
Drug
Lead sponsor
PENTA Foundation
Network
Eligibility
6 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 14, 2026, 4:36 PM EDT
Completed No phase listed Observational

The Effects of Anti-HIV Drugs on the HIV Virus in HIV-Infected Patients

NCT00006442
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 14, 2026, 4:36 PM EDT
Completed Phase 1 Interventional

A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients

NCT00002218
View directory record Official record
Conditions
HIV Infections
Interventions
CI-1012
Drug
Lead sponsor
Parke-Davis
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Palm Springs, California • San Francisco, California • Maitland, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 4:36 PM EDT
Completed Phase 2 Interventional

A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection

NCT00000823
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
22
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 14, 2026, 4:36 PM EDT
Completed Not applicable Interventional

A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients

NCT00002050
View directory record Official record
Conditions
HIV Infections
Interventions
Thymopentin
Drug
Lead sponsor
Immunobiology Research Institute
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Annandale, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 4:36 PM EDT
Not listed No phase listed Observational

Bictegravir in the Elderly Living With HIV (BICEP)

NCT05064020
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 14, 2026, 4:36 PM EDT
Completed No phase listed Observational

HIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs

NCT00001103
View directory record Official record
Conditions
Cognitive Disorders, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
25
States / cities
Menlo Park, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Oct 14, 2026, 4:36 PM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors

NCT00002213
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Amprenavir, Efavirenz
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Berkeley, California • Los Angeles, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 4:36 PM EDT
Completed Phase 1 Interventional

A Study of CI-1012 in HIV-Infected Patients

NCT00002196
View directory record Official record
Conditions
HIV Infections
Interventions
CI-1012
Drug
Lead sponsor
Parke-Davis
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Palm Springs, California • San Francisco, California • Maitland, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 4:36 PM EDT
Active, not recruiting Phase 1 Interventional

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

NCT04340596
View directory record Official record
Conditions
HIV Infection
Interventions
N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 14, 2026, 4:36 PM EDT